eISSN 2234-3814

Table. 1.

Table. 1.

Summary of reported therapy-related leukemia cases with t(11;22)(q23;q13)

Characteristic Present case Ida, et al. [3] Ohnishi, et al. [4] Duhoux, et al. [2] Takeda, et al. [1]
Sex/age (yr) M/76 M/4 F/5 M/65 F/62
Underlying disease Prostate cancer Non-Hodgkin lymphoma Neuroblastoma PTCL NOS and AML with MRC ATL
Leukemia type Acute monocytic leukemia AML without maturation AML with maturation AMML CMML
Latent period (months) 138 67 36 16 10
Cytotoxic exposure Radiotherapy Chemotherapy including ETP Chemotherapy including THP CBDCA, CPA CHOP-14, ESHAP mLSG+mogamulizumab*
Initial complete blood count White blood cell:
0.81 × 109/L
- - White blood cell: 174 × 109/L White blood cell: 4.9 × 109/L
Hemoglobin: 42 g/L Hemoglobin: 80 g/L Hemoglobin: 96 g/L
Platelet: 51 × 109/L Platelet: 73 × 109/L Platelet: 87 × 109/L
Cytogenetics 46,XY,t(11;22)(q23;q13) [13]/46,XY[7] 48,XY,+8,+8,t(11;22) (q23;q13) 46,XX,t(1;22;11) (q44;q13;q23)2,t(10;17) (q22;q21) 46,XY,t(11;22)(q23;q13) [15]/47,idem,+8[2] 46,XX,t(11;22)(q23;q13)
Breakpoint KMT2A exon 10/EP300 exon 15 KMT2A exon 9/EP300 exon 15 KMT2A exon 7/EP300 exon 15 KMT2A exon 10,11/EP300 exon 15 KMT2A exon 10/EP300 exon 15

*a humanized anti-CCR4 antibody.

Abbreviations: PTCL NOS, peripheral T-cell lymphoma not otherwise specified; AML with MRC, acute myeloid leukemia with myelodysplasia-related changes; ATL, adult T-cell leukemia/lymphoma; AMML, acute myelomonocytic leukemia; CMML, chronic myelomonocytic leukemia; ETP, etoposide; THP, pirarubicin; CBDCA, carboplatin; CPA, cyclophosphamide; CHOP-14, cyclophosphamide, doxorubicin, vincristine, and prednisolone; ESHAP, etoposide, methylprednisolone, cytarabine, and cisplatin; mLSG, VCAP (vincristine, cyclophosphamide, doxorubicin, and prednisone), AMP (doxorubicin, ranimustine, and prednisone), and VECP (vindesine, etoposide, carboplatin, and prednisone).

Ann Lab Med 2022;42:693~696

© Ann Lab Med